Asset profile

Shingrix · GSK (GSK)

Indication: shingles prevention

Company

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology,…

Start live analysis of GSK Run 8-agent AI analysis

On the calendar

Jun 2027

~ Jun 2027

GSKGSK

Shingrix: Phase 1/Phase 2 trial NCT06569823 expected to finish collecting primary-endpoint data (topline results usually follow)

Rescheduled — was Nov 1, 2027

Trial primary completionClinicalTrials.govMonth only

Jan 2028

Jan 20, 2028

in 454 days

GSKGSK

Shingrix: Phase 2 trial NCT05775718 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Timeline

Newest first.

Oct 16, 2026

03:23 PM

GSKGSK

Shingrix · NCT06569823 registry update

Trial registry changeClinicalTrials.gov

Oct 8, 2026

07:38 PM

GSKGSK

GSK partners with Viola Davis on "Shingles, actually" education campaign

Partnership / licensing dealCompany press release Open record

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT06801509	Phase 1/2	Not yet recruiting	Nov 10, 2025	540	0 of 1 sites in the United States
NCT06932523	Phase 1/2	Recruiting	Jun 30, 2026	645	0 of 1 sites in the United States
NCT05775718	Phase 2	Recruiting	Jan 20, 2028	55	1 of 1 sites in the United States
NCT06569823	Phase 1/2	Active, not recruiting	Jun 1, 2027	764	0 of 16 sites in the United States
NCT03894969	Phase 2	Completed	Aug 31, 2020	541	0 of 14 sites in the United States
NCT04047979	Phase 2	Completed	Apr 3, 2023	38	1 of 1 sites in the United States

More from GSK

Other drugs and candidates from the same company tracked in this sector.

bepirovirsenchronic hepatitis B (CHB) in adults without cirrhosis on NrtI therapy ≥6 months with suppressed HBV DNA and HBsAg ≤3000 IU/ml boron-based LeuRS inhibitorstuberculosis dostarlimab-gxlyMSI-H/dMMR locally advanced rectal cancer tebipenem HBrcomplicated urinary tract infections (cUTIs) including pyelonephritis VENTANA MMR RxDx PaneldMMR and pMMR solid tumors (colorectal, endometrial, gastric, small intestine, biliary)